Xencor Inc. and Janssen Biotech Inc., already partners on the development of bispecific antibodies against CD28 for prostate cancer, have reached a second agreement licensing to Janssen exclusive development and commercialization rights to Xencor's phase I bispecific antibody, plamotamab, for the treatment of B-cell malignancies, both as a monotherapy and in combination regimens.